Another important mouse model of NSCLC is based on the finding that a fraction of patients whose tumors harbor mutations in the gene encoding the epidermal growth factor receptor (EGFR) [21], [22] are responsive to tyrosine kinase inhibitors (TKIs) that block EGF signaling. This evidence concerns the gene EGF and non-small cell lung carcinoma.